Table 2.
Title | Lesion type | Cells source | Phase of the study | Status | Effects on CNS regeneration |
Clinical study of treatment for acute SCI using cultured bone marrow stromal cells | Cervical SCI | Autologous Bone marrow-MSC | Terminated | 1/2 | Rapid and remarkable recovery of ASIA B and C patients, but gradual or limited in ASIA A patients. |
Autologous mesenchymal stem cell in SCI patients | Complete cervical or thoracic SCI | Autologous bone marrow-MSC | Enrolling by invitation | 2 | Not informed |
Different efficacy between rehabilitation therapy and umbilical cord derived MSCs transplantation in patients with chronic SCI in China | Traumatic SCI | Umbilical cord derived-MSC | Recruiting | 3 | Not informed |
A phase III/IV clinical trial to evaluate the safety and efficacy of bone marrow-derived MSC transplantation in patients with chronic SCI | Cervical SCI | Autologous bone marrow-MSC | Recruiting | 1/2 | Not informed |
Phase I/II trial of autologous bone marrow derived MSCs to patients with SCISafety of autologous adipose derived MSCs in patients with SCI | Traumatic thoracic or lumbar SCIClinical diagnosis of SCI (ASIA A to C) | Autologous bone marrow-MSCAutologous Adipose derived-MSC | RecruitingCompleted | 1/21 | Not informed |
The effect of intrathecal transplantation of autologous adipose tissue derived MSCs in the patients with SCI, phase I clinical study | Clinical diagnosis of SCI | Autologous Adipose derived-MSC | Recruiting | 1 | Not informed |
Phase I, single center, trial to assess safety and tolerability of the intrathecal infusion of ex-vivo expanded bone-marrow derived MSCs for the treatment of SCI | Clinical diagnosis of SCI (ASIA A) | Autologous bone marrow-MSC | Active, not recruiting | 1 | Not informed |
Study the safety and efficacy of bone marrow derived autologous cells for the treatment of SCI | Clinical diagnosis of SCI | Autologous bone marrow-MSC | Recruiting | 1/2 | Not informed |
Surgical transplantation of autologous bone marrow stem cells with glial scar resection for patients of chronic SCI and intra-thecal injection for acute and subacute injury-a preliminary study | Complete spinal cord trans-section | Autologous bone marrow-MSC | Completed | 1/2 | Not informed |
To study the safety and efficacy of autologous bone marrow stem cells in patients with SCI | SCI below C5 (ASIA A to C) | Autologous bone marrow-MSC | Recruiting | 1/2 | Not informed |
Safety of autologous stem cell treatment for SCI in children | Clinical diagnosis of SCI (ASIA A to D) | Bone marrow-MSC | Recruiting | 1 | Not informed |
Autologous bone marrow derived cell transplant in SCI patients | Traumatic SCI | Autologous bone marrow-MSC | Completed | 1/2 | Not informed |
Phase 1 study of autologous bone marrow stem cell transplantation in patients with SCI | Traumatic thoracic or lumbar SCI | Autologous bone marrow-MSC | Not informed | 1 | Not informed |
Phase I pilot study to evaluate the security of local Administration of autologous stem cells obtained from the bone marrow stroma, in traumatic injuries of the spinal cord | Traumatic SCI between C3 and L1 | Autologous bone marrow-MSC | Recruiting | 1 | Not informed |
Feasibility and safety of umbilical cord blood cell transplant into injured spinal cord: an open-labeled, dose-escalating clinical trial | Chronic SCI between C5 and T11 (ASIA A) | Umbilical cord blood mononuclear derived-MSC | Active, not recruiting | 1/2 | Not informed |
Efficacy difference between rehabilitation therapy and umbilical Cord derived transplantation in patients with acute or chronic SCI in China | Clinical diagnosis of SCI | Umbilical cord derived-MSC | Not informed | 2 | Not informed |
Safety and feasibility of umbilical cord blood cell Transplant Into Injured Spinal cord: an open-labeled, dose-escalating clinical trial | Chronic SCI between C5 and T11 (ASIA A) | Umbilical cord derived-MSC | Active, not recruiting | 1/2 | Not informed |
Safety and effect of lithium, umbilical cord blood cells and the combination in the treatment of acute and sub-acute spinal cord injury : a randomized, double-blinded placebo-controlled clinical trial | Acute or Subacute traumatic SCI between C5 and T11 (ASIA A) | Umbilical cord derived-MSC | Active, not recruiting | 1/2 | Not informed |
MSC: Mesenchymal stem cell; CNS: Central nervous system; SCI: Spinal cord injury.